Category: Wall Street Beat
Baxter International looks to sales and margin growth after it spins out its biopharmaceutical arm as Baxalta, likely augmented with acquisitions.
Baxter (NYSE:BAX) said it plans to boost its sales and margin growth after the planned July 1 spinout of its biopharmaceutical division as Baxalta.
Glaukos registers for an initial public offering worth as much as $86 million for its iStent glaucoma treatment.
Glaukos yesterday registered for an initial public offering worth as much as $86.2 million.
The iStent made by Laguna Hills, Calif.-based Glaukos was the 1st micro-invasive glaucoma surgery device to hit the U.S. market. It's a tiny titanium stent designed to alleviate the intra-ocular pressure caused by glaucoma.
Here's a look at some of the top Wall Street stories for medical device companies this week: Boston Scientific aims for double-digit earnings growth; Profound Medical goes public in reverse merger; Pavmed files for $23m IPO; Boston Scientific's Mahoney is bullish on Watchman; Euronext suspends Carmat shares after artificial heart patient dies
The death of the 2nd patient implanted with Carmat's artificial heart died over the weekend, prompting the Euronext exchange to suspend trading in the company's stock.
Development-stage medical device maker Pavmed files for an initial public offering worth $23 million.
The entrepreneurs behind a quartet of medical device companies is betting their formula can cut down on the time and cost of getting medtech to market with a $23 million initial public offering.
Profound Medical becomes a publicly traded with a reverse merger, raising a $24 million private placement to back clinical testing of its prostate cancer ablation device.
Profound Medical yesterday said it's slated to hit the public markets in Canada after a reverse merger, also revealing a $24 million private placement to fuel clinical trial work.
Boston Scientific CEO Mike Mahoney says the company is aiming for double-digit earnings growth each year through 2019.